ATE212546T1 - Behandlung von neurodegenerativen zuständen mittels nimesulide - Google Patents

Behandlung von neurodegenerativen zuständen mittels nimesulide

Info

Publication number
ATE212546T1
ATE212546T1 AT97950672T AT97950672T ATE212546T1 AT E212546 T1 ATE212546 T1 AT E212546T1 AT 97950672 T AT97950672 T AT 97950672T AT 97950672 T AT97950672 T AT 97950672T AT E212546 T1 ATE212546 T1 AT E212546T1
Authority
AT
Austria
Prior art keywords
nimesulide
treatment
neurodegenerative conditions
neurodegeneration
discovery
Prior art date
Application number
AT97950672T
Other languages
English (en)
Inventor
Sinai School Of Medicine Mount
Place Levy
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Application granted granted Critical
Publication of ATE212546T1 publication Critical patent/ATE212546T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT97950672T 1996-11-21 1997-11-19 Behandlung von neurodegenerativen zuständen mittels nimesulide ATE212546T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3333296P 1996-11-21 1996-11-21
US08/831,402 US5985930A (en) 1996-11-21 1997-04-01 Treatment of neurodegenerative conditions with nimesulide
PCT/US1997/021484 WO1998022104A2 (en) 1996-11-21 1997-11-19 Treatment of neurodegenerative conditions with nimesulide

Publications (1)

Publication Number Publication Date
ATE212546T1 true ATE212546T1 (de) 2002-02-15

Family

ID=26709565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97950672T ATE212546T1 (de) 1996-11-21 1997-11-19 Behandlung von neurodegenerativen zuständen mittels nimesulide

Country Status (18)

Country Link
US (3) US5985930A (de)
EP (1) EP0956009B9 (de)
JP (1) JP2001505206A (de)
KR (1) KR20000069061A (de)
AT (1) ATE212546T1 (de)
AU (1) AU725141B2 (de)
BR (1) BR9714303A (de)
CA (1) CA2272249A1 (de)
DE (1) DE69710224T2 (de)
DK (1) DK0956009T3 (de)
ES (1) ES2172822T3 (de)
IL (1) IL129949A (de)
NO (1) NO992374L (de)
NZ (1) NZ335726A (de)
PT (1) PT956009E (de)
SK (1) SK284334B6 (de)
TR (1) TR199901120T2 (de)
WO (1) WO1998022104A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
US7291626B1 (en) 1998-04-09 2007-11-06 John Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
WO2000034521A1 (en) * 1998-12-08 2000-06-15 Boston Probes, Inc. Methods, kits and compositions for the identification of nucleic acids electrostatically bound to matrices
WO2000050391A1 (en) * 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
CA2386190C (en) 1999-10-13 2009-04-14 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
HUP0303857A3 (en) 2000-12-13 2007-07-30 Wyeth Corp Heterocyclic sulifonamide inhibitors of beta amyloid production
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
US20040063752A1 (en) * 2002-05-31 2004-04-01 Pharmacia Corporation Monotherapy for the treatment of amyotrophic lateral sclerosis with cyclooxygenase-2 (COX-2) inhibitor(s)
AU2003237988A1 (en) * 2002-06-13 2003-12-31 Mount Sinai School Of Medicine Of New York University Inhibiting progressive cognitive impairment
US20060041022A1 (en) * 2002-11-06 2006-02-23 Pasinetti Giulio M Treatment of amyotrophic lateral sclerosis with nimesulide
CA2505514A1 (en) * 2002-11-06 2004-05-27 Mount Sinai School Of Medicine Treatment of amyotrophic lateral sclerosis with nimesulide
BRPI0408962A (pt) 2003-03-31 2006-04-04 Wyeth Corp inibidores sulfonamidas heterocìclicos contendo flúor- e trifluoroalquila da produção de beta amilóide e seus derivados
US20090155903A1 (en) * 2004-03-19 2009-06-18 Myriad Genetics, Incorporated Pharmaceutical composition and method
EP2046119A2 (de) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Behandlung von psychiatrischen störungen
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US8377947B2 (en) * 2009-03-16 2013-02-19 Chien-Hung Chen Treating alzheimer's disease and osteoporosis and reducing aging
US8324450B2 (en) 2009-06-02 2012-12-04 Academia Sinica Non-human animal model for frontotemporal lobar degeneration with ubiquitin-positive inclusions (FTLD-U)
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
CA2859364C (en) 2011-12-16 2019-05-07 The Board Of Trustees Of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
EP3536787A1 (de) 2012-06-08 2019-09-11 Translate Bio, Inc. Nukleaseresistente polynukleotide und verwendungen davon
KR20210122917A (ko) 2013-03-14 2021-10-12 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
PL3467108T3 (pl) 2013-03-14 2024-09-30 Translate Bio, Inc. Sposoby oczyszczania informacyjnego rna
EP3033427A4 (de) 2013-08-14 2017-05-31 The Board Of Trustees Of The University Of the Leland Stanford Junior University Zusammensetzungen und verfahren zur bekämpfung von schmerzen
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
EP3122761B1 (de) 2014-03-28 2019-03-06 The Board of Trustees of The Leland Stanford Junior University Manipulierte lichtaktivierte anionenkanalproteine und verfahren zur verwendung davon
PT3134506T (pt) 2014-04-25 2019-10-31 Translate Bio Inc Métodos de purificação de rna mensageiro
WO2016085876A1 (en) 2014-11-25 2016-06-02 The Broad Institute Inc. Clonal haematopoiesis
EP3224381B1 (de) 2014-11-25 2019-09-04 The Brigham and Women's Hospital, Inc. Verfahren zur identifizierung von personen mit einer prädisposition für eine kardiometabolische krankheit oder davon betroffenen personen
WO2017040538A1 (en) 2015-08-31 2017-03-09 The Board Of Trustees Of The Leland Stanford Junior University Compressed sensing high resolution functional magnetic resonance imaging
WO2017100058A1 (en) 2015-12-09 2017-06-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for functional brain circuit analysis
EP3410926A4 (de) 2016-02-01 2019-08-28 The Board of Trustees of the Leland Stanford Junior University Verfahren und systeme zur analyse von funktionellen bildgebungsdaten
EA201991747A1 (ru) 2017-02-27 2020-06-04 Транслейт Био, Инк. НОВАЯ КОДОН-ОПТИМИЗИРОВАННАЯ мРНК CFTR
MX2019013752A (es) 2017-05-16 2020-07-20 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones.
CA3108544A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
MX2021005969A (es) 2018-11-21 2021-09-14 Translate Bio Inc Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr nebulizado.
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
WO2025189030A1 (en) 2024-03-07 2025-09-12 Stellaromics, Inc. Methods and systems for volumetric imaging

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3403096A (en) * 1963-10-02 1968-09-24 Ceskoslovenska Akademie Ved Method and device for separation of a suspension
US4966692A (en) * 1989-05-05 1990-10-30 Flint & Walling, Inc. Filtration system having flow control means and tank adapter with selective venting
US5604260A (en) * 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5543297A (en) * 1992-12-22 1996-08-06 Merck Frosst Canada, Inc. Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
CN1191243C (zh) * 1994-07-27 2005-03-02 范德比尔特大学 用作抗炎剂的二氢苯并呋喃和相关化合物
US5684002A (en) * 1994-09-07 1997-11-04 The Procter & Gamble Company Dihydorbenzofuran and related compounds useful as anti-inflammatory agents
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
US5510361A (en) * 1994-10-20 1996-04-23 The Procter & Gamble Company Di-tert-butylphenol compounds with heterocyclic moiety, useful as anti-inflammatory agents
US5739166A (en) * 1994-11-29 1998-04-14 G.D. Searle & Co. Substituted terphenyl compounds for the treatment of inflammation
CA2164559A1 (en) * 1994-12-09 1996-06-10 Chun-Sing Li 5-methanesulfonamido-6-(2-pyridylthio)-1-indanones as inhibitors of cyclooxygenase-2
DE69529690T2 (de) * 1994-12-21 2003-11-13 Merck Frosst Canada & Co., Halifax Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
AU4479096A (en) * 1995-01-31 1996-08-21 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
ES2183935T3 (es) * 1995-02-13 2003-04-01 Searle & Co Isoxazoles sustituidos para el tratamiento de la inflamacion.
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US5510368A (en) * 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
ITMI962356A1 (it) * 1996-11-13 1998-05-13 Uni Degli Studi Di Brescia D I Uso di composti derivati da molecole ad attivita' antinfiammatoria di tipo non steroideo per la prevenzione e il trattamento di
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide

Also Published As

Publication number Publication date
SK284334B6 (sk) 2005-02-04
AU5361298A (en) 1998-06-10
PT956009E (pt) 2002-07-31
CA2272249A1 (en) 1998-05-28
KR20000069061A (ko) 2000-11-25
JP2001505206A (ja) 2001-04-17
WO1998022104A3 (en) 1998-10-08
TR199901120T2 (xx) 1999-07-21
US20020162130A1 (en) 2002-10-31
DK0956009T3 (da) 2002-05-21
US5985930A (en) 1999-11-16
SK67199A3 (en) 2001-01-18
DE69710224D1 (de) 2002-03-14
BR9714303A (pt) 2000-04-25
WO1998022104A2 (en) 1998-05-28
EP0956009B9 (de) 2002-12-11
EP0956009A1 (de) 1999-11-17
US7226948B2 (en) 2007-06-05
NZ335726A (en) 2000-10-27
ES2172822T3 (es) 2002-10-01
AU725141B2 (en) 2000-10-05
NO992374L (no) 1999-07-21
US6649811B2 (en) 2003-11-18
NO992374D0 (no) 1999-05-18
EP0956009B1 (de) 2002-01-30
US20060059576A1 (en) 2006-03-16
DE69710224T2 (de) 2002-10-02
IL129949A0 (en) 2000-02-29
IL129949A (en) 2003-05-29

Similar Documents

Publication Publication Date Title
ATE212546T1 (de) Behandlung von neurodegenerativen zuständen mittels nimesulide
ATE290782T1 (de) Kombination von bisphosphonat und tetracyclin
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
RU93048466A (ru) Применение бензотиофенов для профилактики и лечения остеопороза и фармацевтическая композиция на их основе
ES2135083T3 (es) Trifeniletilenos para la prevencion y el tratamiento de la osteoporosis.
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
DE69939864D1 (de) Ppar-gamma modulatoren
ATE303993T1 (de) 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe
EP0840608A4 (de) Behandlung und vorbeugung von neoplasmen mit salzen von aminoimidazolcarboxamid und 5-amino-oder substituierten amino 1,2,3-triazolen
NO20001413D0 (no) Synergistisk sammensetning samt fremgangsmåter ved behandling av neoplasier og svulster samt for å restaurere eller forsterke hematopoese
ATE284682T1 (de) Verwendung von 2-methoxyestradiol als fungizide
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
ATE256666T1 (de) Zusammensetzungen und methoden zur verhinderung des zelltods
FI961380A7 (fi) Koostumuksia virusten aiheuttamien kasvainten ehkäisemiseksi ja hoitam iseksi
BR9707844A (pt) Combinação de desidroepiandrosterona e inibidores de aromatase e emprego desta combinação para a preparação de um medicamento para o tratamento de uma deficiência de androgênio relativa e absoluta no homem
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE208202T1 (de) Verwendung von dimeticon zur behandlung der konstipation
ATE193206T1 (de) Zusammensetzung zur behandlung oder vorbeugung von herpes
FI944687A7 (fi) Koostumus likinäköisyyden ennaltaehkäisemiseksi ja hoitamiseksi
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE69715878D1 (de) Formulierung zur behandlung und/oder vorbeugung von dementia
NO20026076D0 (no) Kombinert terapi mot tumorer innbefattende substituerte akryloyldistamycinderivater, taksaner og/eller antimetabolitter
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee